Big Money Sentiment decreased to 0.94 in 2018 Q4. It has change of 1.86, from 2018Q3’s 2.8. The ratio worsened due to Marrone Bio Innovations, Inc. positioning: 6 sold and 11 reduced. 8 funds took stakes and 8 increased stakes. Investors holded 46.32 million in 2018Q3 but now own 46.51 million shares or 0.40% more.
Jpmorgan Chase And holds 0% of its capital in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 13,934 shs. Tower Research Ltd Company (Trc) owns 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 12,346 shs. Legal And General Pcl accumulated 0% or 8,134 shs. New York State Common Retirement Fund accumulated 21,100 shs. National Bank & Trust Of Montreal Can accumulated 0% or 770 shs. Intll Gp Inc reported 35,915 shs. Blackrock invested in 0% or 2.80 million shs. Rhumbline Advisers holds 0% of its capital in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 68,021 shs. Hanson Mcclain Incorporated owns 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 10,766 shs. The New York-based Bancshares Of Mellon Corp has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Deutsche Comml Bank Ag stated it has 71,302 shs or 0% of all its holdings. Bnp Paribas Arbitrage accumulated 0% or 964 shs. Ameritas Investment Prtn has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Raymond James Advsrs Inc reported 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Fairpointe Cap Limited Co reported 132,240 shs.

Marrone Bio Innovations, Inc. had 1 sale and 0 buys since September 24, 2018. This’s net activity of $2.35 million.

On April, 4 Marrone Bio Innovations, Inc. (NASDAQ:MBII)’s earnings report is expected by WallStreet, Faxor reports. Analysts predict $-0.05 earnings per share, which is $0.19 up or 79.17 % from 2018’s $-0.24 earnings per share. After $-0.04 EPS report last quarter, Wall Street now forecasts 25.00 % negative EPS growth of Marrone Bio Innovations, Inc.. MBII touched $1.59 during the last trading session after $0.03 change.Marrone Bio Innovations, Inc. is uptrending after having risen 44.14% since March 23, 2018. MBII has 119,966 volume or 6.55% up from normal. MBII outperformed by 39.77% the S&P500.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally.The firm is valued at $175.99 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.Currently it has negative earnings. The company's products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

For more Marrone Bio Innovations, Inc. (NASDAQ:MBII) news posted recently go to: Zacks.com, Seekingalpha.com, Globenewswire.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Marrone Bio (MBII) Q3 Earnings In Line, Sales Trail Estimates – Zacks.com” posted on November 14, 2018, “Marrone Bio Innovations, Inc. (MBII) CEO Pamela Marrone on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 13, 2018, “Marrone Bio Innovations Appoints Barner Jones as New Director of National Sales and Account Management – GlobeNewswire” with a publish date: October 17, 2018, “Marrone Bio Innovations Announces Zequanox® Distribution Partnership – GlobeNewswire” and the last “MARRONE BIO (MBII) Investor Presentation – Slideshow – Seeking Alpha” with publication date: November 14, 2018.